Is CORT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CORT. It does not provide personalized investment advice.

CORT (Corcept Therapeutics Inc.) Stock Analysis - Financials

Corcept Therapeutics Inc. (CORT) is a publicly traded Healthcare sector company. As of October 26, 2026, CORT trades at $90.24 with a market cap of $9.28B and a P/E ratio of 117.20. CORT moved +6.20% today. Year to date, CORT is +146.72%; over the trailing twelve months it is +17.65%. Its 52-week range spans $28.66 to $126.38. Analyst consensus is buy with an average price target of $141.00. Rallies surfaces CORT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are CORT's key financials?

CORT financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CORT recently traded at $90.24. Market cap is $9.28B. P/E ratio is 117.20. Revenue is $741.17M.

CORT Key Metrics

Key financial metrics for CORT
Metric	Value
Price	$90.24
Market Cap	$9.28B
P/E Ratio	117.20
EPS	$1.01
Dividend Yield	0.00%
52-Week High	$126.38
52-Week Low	$28.66
Volume	285.03K
Avg Volume	0
Revenue (TTM)	$741.17M
Net Income	$106.11M
Gross Margin	98.19%

CORT Analyst Consensus

5 analysts cover CORT: 0 strong buy, 4 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $141.00.

Common questions about CORT

What are CORT's key financials?: CORT financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CORT recently traded at $90.24. Market cap is $9.28B. P/E ratio is 117.20. Revenue is $741.17M.
Is CORT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CORT. It does not provide personalized investment advice.